Pathophysiology of migraine

Annals of Indian Academy of Neurology

Volumn 15, Issue SUPPL., 2012, Pages 15-22

  Goadsby, Peter J ^a  

^a UCSF Headache Center   (United States)

Author keywords

Brainstem; dyshabituation; migraine

Indexed keywords

5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ADX 10059; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; DIHYDROERGOTAMINE; GLUTAMIC ACID; LY 466195; NEUROPEPTIDE; NITRIC OXIDE; PLACEBO; PLASMA PROTEIN; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SUBSTANCE P; TEZAMPANEL; TONABERSAT; TOPIRAMATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

BRAIN REGION; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CHROMOSOME 19P; CLINICAL FEATURE; DISEASE CLASSIFICATION; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; FAMILIAL HEMIPLEGIC MIGRAINE; GENE MUTATION; GENETIC LINKAGE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPOTHALAMUS; MIGRAINE; MIGRAINE AURA; NEUROANATOMY; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY STIMULATION; SKULL; SPREADING CORTICAL DEPRESSION; THALAMUS; TRIGEMINUS GANGLION; VASODILATATION;

EID: 84872533638     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.99993     Document Type: Review

References (85)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. N Engl J Med 2002;346:257-70
2. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience 2009;161:327-41
3. van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD. Migraine: Gene mutations and functional consequences. Curr Opin Neurol 2007;20:299-305
4. Russell MB, Iselius L, Olesen J. Investigation of the inheritance of migraine by complex segregation analysis. Hum Genet 1995;96:726-30
5. Scher AI, Terwindt GM, Verschuren WM, Kruit MC, Blom HJ, Kowa H, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol 2006;59:372-5
6. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10
7. Diener HC, Kurth T, Dodick D. Patent foramen ovale and migraine. Curr Pain Headache Rep 2007;11:236-40
8. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: Systematic review and meta-analysis. Br Med J 2009;339:b3914
9. Kors EE, Terwindt GM, Vermeulen FL, Fitzsimons RB, Jardine PE, Heywood P, et al. Delayed cerebral edema and fatal coma after minor head trauma: Role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol 2001;49:753-60
10. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543-52
11. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/ K+ pump a2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003;33:192-6
12. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A causes familial hemiplegic migraine. Lancet 2005;366:371-7
13. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, Kaja S, Broos LA, Cesetti T, et al. A Cacna1a knock-in migraine mouse model with increased susceptibility to cortical spreading depression. Neuron 2004;41:701-10
14. Park JW, Moon HS, Akerman S, Holland PR, Lasalandra M, Andreou AP, et al. Blunted trigeminovascular nociceptive responses in mice with the CACNA1A mutation. Headache 2010;50(Suppl 1):61
15. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994;117:199-210
16. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 1941;46:331-9
17. Leao AA. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944;7:359-90
18. Olesen J. Cerebral and extracranial circulatory disturbances in migraine: Pathophysiological implications. Cerebrovasc Brain Metab Rev 1991;3:1-28
19. Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, Baum MJ, et al. Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest 2009;119:99-109
20. Goadsby PJ, Giffin N, Kaube H, Afridi S. Ketamine reduces the severity of prolonged migraine aura: Support for the glutamate hypothesis of aura. Neurology 2011;76(Suppl 4): A443
21. Smith MI, Read SJ, Chan WN, Thompson M, Hunter AJ, Upton N, et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: Inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000;20:546-53
22. Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA. SB-220453, a potential novel antimigraine compound, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 1999;20:92-9
23. Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG. Randomized double blind, placebo-controlled proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009;29:742-50
24. Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: A randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 2009;8:718-23
25. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: Impact in migraine aura. Neuro Report 2005;16:1383-7
26. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59:652-61
27. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004;24:1049-56
28. Andreou AP, Goadsby PJ. Topiramate in the treatment of migraine: A kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 2011;31:1343-1358
29. Petersen KA, Nilsson E, Olesen J, Edvinsson L. Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 2005;25:424-32
30. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6
31. Feindel W, Penfield W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960;10:555-63
32. McNaughton FL, Feindel WH. Innervation of intracranial structures: A reappraisal. In: Rose FC, editor. Physiological aspects of Clinical Neurology. Oxford: Blackwell Scientific Publications; 1977. p. 279-93
33. Moskowitz MA, Cutrer FM. SUMATRIPTAN: A receptor-targeted treatment for migraine. Ann Rev Med 1993;44:145-54
34. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-42
35. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991;44:97-112
36. Peroutka SJ. Neurogenic inflammation and migraine: Implications for therapeutics. Mol Interv 2005;5:306-13
37. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatr 1960;23:23-32
38. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Brain 2000;123:1703-9
39. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-3
40. Diaz Insa S, Goadsby PJ, Fortea J, Falques M, Zanchin G, Vila C. Allodynia does not affect the efficacy of almotriptan when given early in migraine: Data from the 'Act when Mild' study. Int J Neurosci 2011;121:655-661
41. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain 1996;119:249-56
42. Goadsby PJ, Gundlach AL. Localization of [3H]-dihydroergotamine binding sites in the cat central nervous system: Relevance to migraine. Ann Neurol 1991;29:91-4
43. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann Neurol 2004;56:371-81
44. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:69-75
45. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
46. Edvinsson L, Ekman R, Goadsby PJ. Measurement of vasoactive neuropeptides in biological materials: Problems and pitfalls from 30 years of experience and novel future approaches. Cephalalgia 2010;30:761-6
47. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56
48. Knight YE, Edvinsson L, Goadsby PJ. Blockade of CGRP release after superior sagittal sinus stimulation in cat: A comparison of avitriptan and CP122,288. Neuropeptides 1999;33:41-6
49. Knight YE, Edvinsson L, Goadsby PJ. 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity. Neuropharmacol 2001;40:520-5
50. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:761-6
51. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: A c-fos immunocytochemical study. J Anat 1997;190:367-75
52. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991;114:1001-11
53. Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 2002;125:1496-509
54. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurones to cervical input after stimulation of the dura mater. Brain 2003;126:1801-13
55. Le Doare K, Akerman S, Holland PR, Lasalandra MP, Classey JD, Knight YE, et al. Occipital afferent activation of second order neurons in the trigeminocervical complex in rat. Neurosci Lett 2006;403:73-7
56. Bartsch T, Goadsby PJ. Anatomy and physiology of pain referral in primary and cervicogenic headache disorders. Headache Curr 2005;2:42-8
57. Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: A comparative study of monkey and cat. J Anat 1999;194:579-88
58. Andreou AP, Summ O, Charbit AR, Romero Reyes M, Goadsby PJ. Animal models of headache- From bedside to bench and back to beside. Expert Rev Neurother 2010;10:389-411
59. Goadsby PJ, Akerman S, Storer RJ. Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann Neurol 2001;50:804-7
60. Classey JD, Bartsch T, Goadsby PJ. Distribution of 5-HT1B, 5-HT1D and 5-HT1F receptor expression in rat trigeminal and dorsal root ganglia neurons: Relevance to the selective anti-migraine effect of triptans. Brain Res 2010;1361:76-85
61. Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 1999;19:851-8
62. Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial. Cephalalgia 2010;30:1170-8
63. Farkkila M, Diener H-C, Lainez JM, Schoenen J, Pilgrim AJ. Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain 2010;11(Suupl 1):209
64. Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 2009;18:789-803
65. Marin JC, Goadsby PJ. Glutamatergic fine tuning with ADX-10059- A novel therapeutic approach for migraine? Expert Opin Investig Drugs 2010;19:555-61
66. Andreou AP, Holland PR, Goadsby PJ. Activation of GluR5 kainate receptors inhibits neurogenic dural vasodilation in animal model of trigeminovascular activation. Br J Pharmacol 2009;157:464-73
67. Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol Exp Ther 2006;318:772-81
68. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24:596-602
69. Zagami AS, Lambert GA. Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. Exp Brain Res 1990;81:552-66
70. Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: A role in migraine? Brain 2005;128:86-97
71. Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: A functional genetic link for migraine? J Neurosci 2002;22(RC213):1-6
72. Goadsby PJ, Cittadini E, Cohen AS. Trigeminal autonomic cephalalgias: Paroxysmal hemicrania, SUNCT/SUNA and hemicrania continua. Sem Neurol 2010;30:186-91
73. Charbit AR, Akerman S, Holland PR, Goadsby PJ. Neurons of the dopaminergic/CGRP A11 cell group modulate neuronal firing in the trigeminocervical complex: An electrophysiological and immunohistochemical study. J Neurosci 2009;29:12532-41
74. Holland PR, Goadsby PJ. The hypothalamic orexinergic system: Pain and primary headaches. Headache 2007;47:951-62
75. Gowers WR. A Manual of Diseases of the Nervous System. Philadelphia: P. Blakiston, Son and Co.; 1888
76. Henrik S, Steffen B, Wienecke T, Kruuse C, Olesen J, Messoud A. PACAP38 induces migraine-like attacks and vasodilatation- A causative role in migraine pathogenesis? Brain 2009;132:16-25
77. Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia 2008;28:226-36
78. Goadsby PJ. The Vascular Theory of Migraine-a great story wrecked by the facts. Brain 2009;132:6-7
79. Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 2008;131:2192-200
80. Sprenger T, Goadsby PJ. What has functional neuroimaging done for primary headache and for the clinical neurologist? J Clin Neurosci 2010;17:547-53
81. Goadsby PJ, Lambert GA, Lance JW. Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Res 1982;249:247-54
82. Goadsby PJ, Piper RD, Lambert GA, Lance JW. The effect of activation of the nucleus raphe dorsalis (DRN) on carotid blood flow. I The Monkey. Am J Physiol 1985;248: R257-62
83. Schoenen J, Ambrosini A, Sandor PS, Maertens de Noordhout A. Evoked potentials and transcranial magnetic stimulation in migraine: Published data and viewpoint on their pathophysiologic significance. Clin Neurophysiol 2003;114:955-72
84. Angelini L, de Tommaso M, Guido M, Hu K, Ivanov P, Marinazzo D, et al. Steady-state visual evoked potentials and phase synchronization in migraine patients. Phys Rev Lett 2004;93:038103
85. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia 2004;24(Suppl 1):1-160